Chronic Disease Control

Quantitative assessment of hepatic steatosis in metabolic dysfunction-associated steatotic liver disease using ultrasound attenuation analysis

  • Biqing ZHAO ,
  • Yuli ZHU ,
  • Hairong LIU ,
  • Peipei YIN ,
  • Feifei LIU ,
  • Can LIU ,
  • Kun WANG
Expand
  • 1.Department of Ultrasound Medicine,Binzhou Medical University Hospital,Binzhou 256603,Shandong,China
    2.Department of Ultrasound,Fudan University Zhongshan Hospital,Shanghai 200032,Shanghai,China
    3.Department of Ultrasound Medicine,Binzhou Medical University Yantai Affiliated Hospital,Yantai 264100,Shandong,China

Received date: 2025-11-06

  Revised date: 2025-12-31

  Accepted date: 2026-01-04

  Online published: 2026-03-26

Abstract

Objective To evaluate the diagnostic performance of ultrasound attenuation analysis (USAT) for quantifying hepatic steatosis in metabolic dysfunction-associated steatotic liver disease (MASLD), the CT liver-to-spleen attenuation ratio (CTL/S) was used as the reference standard. Methods In this prospective study, we consecutively enrolled adult participants who were clinically suspected of having MASLD and healthy control volunteers. All participants underwent both USAT imaging and non-contrast CT during the same visit. The repeatability of USAT measurements was evaluated using Bland-Altman analysis and the intraclass correlation coefficient (ICC). The association between USAT values and the grade of hepatic steatosis was analyzed by means of Spearman′s rank correlation. Factors influencing USAT values were explored through linear regression analysis. The diagnostic accuracy of USAT was determined via receiver operating characteristic (ROC) curve analysis and compared with a clinical prediction model using the DeLong test. Results Among the 268 enrolled participants, CTL/S grading identified 64 individuals with normal liver and 204 with MASLD, which included 78 cases of mild, 69 cases of moderate, and 57 cases of severe steatosis. Bland-Altman analysis and ICC assessment demonstrated excellent agreement for USAT measurements. USAT values were strongly inversely correlated with CTL/S (r = -0.850, 95%CI: -0.880 - -0.813) and strongly positively correlated with steatosis grade (r = 0.846, 95%CI: 0.807 - 0.878; both P < 0.001). The median USAT value increased progressively as the severity of steatosis increased: 0.55 dB/cm/MHz (normal liver), 0.67 dB/cm/MHz (mild steatosis), 0.77 dB/cm/MHz (moderate steatosis), and 0.86 dB/cm/MHz (severe steatosis), with significant inter-group differences (all P < 0.001). Based on simple and multiple linear regression analyses, fatty liver grading was found to be the determining factor for USAT. The optimal USAT cut-off values for detecting mild, moderate, and severe steatosis were 0.61, 0.71, and 0.82 dB/cm/MHz, respectively, yielding areas under the curve (AUCs) of 0.90, 0.88, and 0.87, which were significantly superior to those of the clinical prediction model (DeLong test, all P < 0.01). Conclusions USAT, a non-invasive, practical, and novel technique, offers both qualitative and quantitative assessment of hepatic steatosis in MASLD. It has significant potential for broad adoption in screening and quantifying hepatic fat content.

Cite this article

Biqing ZHAO , Yuli ZHU , Hairong LIU , Peipei YIN , Feifei LIU , Can LIU , Kun WANG . Quantitative assessment of hepatic steatosis in metabolic dysfunction-associated steatotic liver disease using ultrasound attenuation analysis[J]. The Journal of Practical Medicine, 2026 , 42(6) : 1008 -1017 . DOI: 10.3969/j.issn.1006-5725.2026.06.013

References

[1] ESLAM M, SANYAL A J, GEORGE J. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158(7): 1999-2014.e1. doi:10.1053/j.gastro.2019.11.312 .
[2] ESLAM M, FAN J G, YU M L, et al. The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease[J]. Hepatol Int, 2025, 19(2): 261-301. doi:10.1007/s12072-024-10774-3 .
[3] SUGIMOTO K, MORIYASU F, OSHIRO H, et al. The role of multiparametric US of the liver for the evaluation of nonalcoholic steatohepatitis[J]. Radiology, 2020, 296(3): 532-540. doi:10.1148/radiol.2020192665 .
[4] DRO?D? K, NABRDALIK K, HAJZLER W, et al. Metabolic-associated fatty liver disease (MAFLD), diabetes, and cardiovascular disease: Associations with fructose metabolism and gut microbiota[J]. Nutrients, 2021, 14(1): 103. doi:10.3390/nu14010103 .
[5] 郭智萍. 脂肪肝的定量影像学评价[J]. 中华健康管理学杂志, 2020, 14(6): 583-586. doi:10.3760/cma.j.cn115624-20200507-00348 .
[6] JUNG J, HAN A, MADAMBA E, et al. Direct comparison of quantitative US versus controlled attenuation parameter for liver fat assessment using MRI proton density fat fraction as the reference standard in patients suspected of having NAFLD[J]. Radiology, 2022, 304(1): 75-82. doi:10.1148/radiol.211131 .
[7] WANG M, TANG S, LI G, et al. Comparative study of ultrasound attenuation analysis and controlled attenuation parameter in the diagnosis and grading of liver steatosis in non-alcoholic fatty liver disease patients[J]. BMC Gastroenterol, 2024, 24(1): 81. doi:10.1186/s12876-024-03160-8 .
[8] 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 中国非酒精性脂肪性肝病诊疗指南(2010年修订版)[J/OL]. 中国医学前沿杂志(电子版), 2012, 4(7): 4-10. doi:10.3969/j.issn. 1674-7372.2012.07.002 .
[9] LEE J H, KIM D, KIM H J, et al. Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease[J]. Dig Liver Dis, 2010, 42(7): 503-508. doi:10.1016/j.dld. 2009.08.002 .
[10] LONG M T, PEDLEY A, COLANTONIO L D, et al. Development and validation of the Framingham steatosis index to identify persons with hepatic steatosis[J]. Clin Gastroenterol Hepatol, 2016, 14(8): 1172-1180.e2. doi:10.1016/j.cgh.2016.03.034 .
[11] WANG J, XU C, XUN Y, et al. ZJU index: A novel model for predicting nonalcoholic fatty liver disease in a Chinese population[J]. Sci Rep, 2015, 5: 16494. doi:10.1038/srep16494 .
[12] MAK L Y, HUI R W, FUNG J, et al. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B[J]. J Hepatol, 2020, 73(4): 800-806. doi:10.1016/j.jhep.2020.05.040 .
[13] 赵冉, 沙卫红. 代谢相关脂肪性肝病的概念变更及其对临床实践的影响[J]. 实用医学杂志, 2022, 38(19): 2390-2394. doi:10.3969/j.issn.1006-5725.2022.19.003 .
[14] HERNAEZ R, LAZO M, BONEKAMP S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta-analysis[J]. Hepatology, 2011, 54(3): 1082-1090. doi:10.1002/hep.24452 .
[15] DULAI P S, SIRLIN C B, LOOMBA R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice[J]. J Hepatol, 2016, 65(5): 1006-1016. doi:10.1016/j.jhep. 2016. 06.005 .
[16] KINNER S, REEDER S B, YOKOO T. Quantitative imaging biomarkers of NAFLD[J]. Dig Dis Sci, 2016, 61(5): 1337-1347. doi:10.1007/s10620-016-4037-1 .
[17] STAREKOVA J, HERNANDO D, PICKHARDT P J, et al. Quantification of liver fat content with CT and MRI: State of the art[J]. Radiology, 2021, 301(2): 250-262. doi:10.1148/radiol.2021204288 .
[18] WONG V W, CHAN W K, CHITTURI S, et al. Asia-Pacific Working Party on non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment[J]. J Gastroenterol Hepatol, 2018, 33(1): 70-85. doi:10.1111/jgh.13857 .
[19] JIANG M, ZHANG X, WU X, et al. The diagnostic value of novel ultrasound attenuation analysis in detecting liver steatosis identified by the controlled attenuation parameter: A diagnostic accuracy study[J]. Ann Transl Med, 2023, 11(2): 38. doi:10.21037/atm-22-5821 .
[20] 马雪颖, 马向明. 非酒精性脂肪肝患者肝脏纤维化血清学测评方法的研究进展[J]. 实用医学杂志, 2025, 41(15): 2290-2303. doi:10.3969/j.issn.1006-5725.2025.15.002 .
[21] 汪许红, 张盛敏, 杨敏, 等. 新型定量超声技术在非酒精性脂肪肝患者肝脏脂肪变性定量中的应用[J]. 中国超声医学杂志, 2021, 37(11): 1253-1257. doi:10.3969/j.issn.1002-0101. 2021.11.016 .
[22] MOTAMED N, NIKKHAH M, KARBALAIE NIYA M H, et al. The ability of the Framingham steatosis index (FSI) to predict non-alcoholic fatty liver disease (NAFLD): A cohort study[J]. Clin Res Hepatol Gastroenterol, 2021, 45(6): 101567. doi:10.1016/j.clinre.2020.10.011 .
[23] CHANG J W, LEE H W, KIM B K, et al. Hepatic steatosis index in the detection of fatty liver in patients with chronic hepatitis B receiving antiviral therapy[J]. Gut Liver, 2021, 15(1): 117-127. doi:10.5009/gnl19301 .
[24] CHO Y K, KIM M, KIM Y J, et al. Predictive value of the Framingham steatosis index for cardiovascular risk: A nationwide population-based cohort study[J]. Front Cardiovasc Med, 2023, 10: 1163052. doi:10.3389/fcvm.2023.1163052 .
[25] WU C, LOH Y H, HUANG H, et al. ZJU index as a predictive tool for diabetes incidence: Insights from a population-based cohort study[J]. Diabetes Metab Syndr Obes, 2024, 17: 715-724. doi:10.2147/DMSO.S446042 .
Outlines

/